获得的二次HER2突变增强HER2/MAPK信号传递并促进对乳腺癌中HER2激酶抑制的抵抗
Arnaldo Marín1,2,3, Abdullah Al Mamun4, Hima Patel3
1UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas.
Cancer research
|July 5, 2023
概括
除了HER2T798I之外的二次HER2突变,在乳腺癌中导致对HER2氨酸激酶抑制剂 (TKI) 的耐药性. 结合HER2和MEK抑制可以克服这种获得的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物耐药性 药物耐药性 药物耐药性
背景情况:
- HER2突变是乳腺癌的一个子集的关键驱动因素.
- 像尼拉替尼这样的HER2氨酸激酶抑制剂 (TKIs) 准这些突变,但获得的耐药性是常见的.
- 在TKI治疗期间经常出现二次HER2突变,限制了治疗的持续时间.
研究的目的:
- 调查二次HER2突变 (不包括HER2T798I) 在获得对HER2TKI耐药性的作用.
- 了解这些二次突变赋予耐药性的机制.
- 确定潜在的治疗策略来克服TKI耐药性.
主要方法:
- 对 HER2 突变乳腺癌的基因组分析,这些乳腺癌在涅拉替尼治疗中进展.
- 功能性研究涉及表达特定二次HER2突变的工程细胞系.
- 计算结构建模以评估药物结合和蛋白质激活.
- 获得突变的细胞中TKI敏感性的药理学评估.
主要成果:
- 二次HER2突变HER2T862A和HER2L755S被确定为耐拉提尼布耐药性的驱动因素.
- 这些突变增强了HER2激活,并降低了内拉替尼的结合亲和力.
- 双 HER2 突变对大多数 HER2 TKIs 产生了耐药性,但对 mobocertinib 和 poziotinib 保持了敏感性.
- 在双变异细胞中观察到增强的MEK/ERK信号传递.
结论:
- 二次HER2突变在获得对HER2TKI耐药性的过程中起着因果作用.
- 联合抑制HER2和MEK信号传递可以克服这些突变介导的抗性.
- 这些发现为获得耐药性的HER2突变乳腺癌提供了潜在的治疗策略.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.7K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
